PT  - JOURNAL ARTICLE
AU  - Gonzalez-Reiche, Ana S.
AU  - Alshammary, Hala
AU  - Schaefer, Sarah
AU  - Patel, Gopi
AU  - Polanco, Jose
AU  - Amoako, Angela A.
AU  - Rooker, Aria
AU  - Cognigni, Christian
AU  - Floda, Daniel
AU  - van de Guchte, Adriana
AU  - Khalil, Zain
AU  - Farrugia, Keith
AU  - Assad, Nima
AU  - Zhang, Jian
AU  - Alburquerque, Bremy
AU  - Sominsky, Levy
AU  - Srivastava, Komal
AU  - Sebra, Robert
AU  - Ramirez, Juan David
AU  - Banu, Radhika
AU  - Shrestha, Paras
AU  - Paniz-Mondolfi, Alberto
AU  - Sordillo, Emilia Mia
AU  - Simon, Viviana
AU  - van Bakel, Harm
TI  - Intrahost evolution and forward transmission of a novel SARS-CoV-2 Omicron BA.1 subvariant
AID  - 10.1101/2022.05.25.22275533
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.25.22275533
4099  - http://medrxiv.org/content/early/2022/05/27/2022.05.25.22275533.short
4100  - http://medrxiv.org/content/early/2022/05/27/2022.05.25.22275533.full
AB  - Persistent SARS-CoV-2 infections have been reported in immune-compromised individuals and people undergoing immune-modulatory treatments. It has been speculated that the emergence of antigenically diverse SARS-CoV-2 variants such as the Omicron variant may be the result of intra-host viral evolution driven by suboptimal immune responses, which must be followed by forward transmission. However, while intrahost evolution has been documented, to our knowledge no direct evidence of subsequent forward transmission is available to date.Here we describe the emergence of an Omicron BA.1 sub-lineage with 8 additional amino acid substitutions within the spike (E96D, L167T, R346T, L455W, K458M, A484V, H681R, A688V) in an immune-compromised host along with evidence of 5 forward transmission cases. Our findings show that the Omicron BA.1 lineage can further diverge from its exceptionally mutated genome during prolonged SARS-CoV-2 infection; highlighting an urgent need to employ therapeutic strategies to limit duration of infection and spread in vulnerable patients.Competing Interest StatementThe Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays listing Viviana Simon as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Robert Sebra is VP of Technology Development and a stockholder at Sema4, a Mount Sinai Venture. This work, however, was conducted solely at Icahn School of Medicine at Mount Sinai.Funding StatementThe work reported was in part supported by a contract from the National Institute of Allergy and Infectious Diseases (75N93021C00014, Option 12A) awarded to the Center for Research on Influenza Pathogenesis and Transmission (a Center of Excellence for Influenza Research and Response) as part of the SARS-CoV-2 Assessment of Viral Evolution (SAVE) Program, a contract from the National Institute of Allergy and Infectious Diseases (HHSN272201400008C) awarded to the Center for Research on Influenza Pathogenesis (a Center of Excellence for Influenza Research and Surveillance), philanthropic donations from the JPB Foundation, a research grant (2020-215611 [5384]) from the Open Philanthropy Project, and awards (S10OD026880 and S10OD030463) from the NIH Office of Research Infrastructure Programs.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were reviewed and approved by the Mount Sinai Hospital Institutional Review Board for the collection and viral genome sequencing of residual diagnostic specimens by the Pathogen Surveillance Program (protocol HS# 13-00981).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript or available upon reasonable request to the authors https://www.gisaid.org